Given their efficacy in terms of tumor cytotoxicity in xenograft tumor models, future clinical evaluations of allogeneic CAR/sIL-15 Vδ1 T cells in the treatment of GPC-3-expressing tumors, including HCC, is highly expected, since it might offer a safe and effective off-the-self product [33]. This evidence concerns the gene GPC3 and neoplasm.